- Home
- ICCM vs VANI Comparison
ICCM vs VANI Comparison
Compare ICCM & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- VANI
- Stock Information
- Founded
- ICCM 2006
- VANI 1998
- Country
- ICCM Israel
- VANI United States
- Employees
- ICCM N/A
- VANI N/A
- Industry
- ICCM
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ICCM
- VANI Health Care
- Exchange
- ICCM Nasdaq
- VANI Nasdaq
- Market Cap
- ICCM 75.8M
- VANI 69.3M
- IPO Year
- ICCM N/A
- VANI 2014
- Fundamental
- Price
- ICCM $1.41
- VANI $1.15
- Analyst Decision
- ICCM Strong Buy
- VANI Strong Buy
- Analyst Count
- ICCM 2
- VANI 1
- Target Price
- ICCM $2.70
- VANI $3.00
- AVG Volume (30 Days)
- ICCM 379.2K
- VANI 83.2K
- Earning Date
- ICCM 04-02-2025
- VANI 03-25-2025
- Dividend Yield
- ICCM N/A
- VANI N/A
- EPS Growth
- ICCM N/A
- VANI N/A
- EPS
- ICCM N/A
- VANI N/A
- Revenue
- ICCM $3,671,000.00
- VANI N/A
- Revenue This Year
- ICCM $10.03
- VANI N/A
- Revenue Next Year
- ICCM $62.68
- VANI N/A
- P/E Ratio
- ICCM N/A
- VANI N/A
- Revenue Growth
- ICCM 26.02
- VANI N/A
- 52 Week Low
- ICCM $0.48
- VANI $1.01
- 52 Week High
- ICCM $1.66
- VANI $7.80
- Technical
- Relative Strength Index (RSI)
- ICCM 60.09
- VANI 43.02
- Support Level
- ICCM $1.22
- VANI $1.12
- Resistance Level
- ICCM $1.66
- VANI $1.19
- Average True Range (ATR)
- ICCM 0.09
- VANI 0.03
- MACD
- ICCM 0.01
- VANI 0.00
- Stochastic Oscillator
- ICCM 43.18
- VANI 42.86
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.